ESCC Clinical Trials

25 clinical trials for ESCC across international registries, including 9 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Integrated Cf-miRNA and Exosomal miRNA Signature for Early Detection of Esophageal Squamous Cell Carcinoma — RECRUITING
• Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC) — RECRUITING · NA
• A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors — RECRUITING · PHASE1
• A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors — RECRUITING · PHASE1
• Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma — RECRUITING · PHASE2
• A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors — RECRUITING · PHASE1
• Lymph Node Metastasis in Early Esophageal Squamous Cell Carcinoma — RECRUITING
• AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients — RECRUITING · PHASE2
• Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma — RECRUITING
• Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma — NOT_YET_RECRUITING · PHASE2
• Adebrelimab Plus Full-course Neoadjuvant Therapy for Resectable Locally Advanced ESCC (Phase 2) — NOT_YET_RECRUITING · PHASE2
• Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma — NOT_YET_RECRUITING · PHASE2
• Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2 — NOT_YET_RECRUITING · PHASE2
• SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy — NOT_YET_RECRUITING · PHASE2
• Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma — NOT_YET_RECRUITING · PHASE2
• Adebrelimab Neoadjuvant Treatment for Resectable ESCC — NOT_YET_RECRUITING · NA
• TAS-102 Plus Radiotherapy in Elderly ESCC — NOT_YET_RECRUITING · PHASE1
• Concurrent Radiotherapy Following Induction Chemoimmunotherapy for Locally Advanced Esophageal Cancer — COMPLETED · PHASE2
• Immunotherapy Combined With Chemoradiotherapy for First-line Treatment of Esophageal Squamous Cell Carcinoma（ChinECR） — OTHER · NA
• Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants — TERMINATED · PHASE1
• Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation — NOT_YET_RECRUITING · PHASE2
• DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer — OTHER · NA
• Efficacy and Safety of Tislelizumab and Nab-paclitaxel Combined With Low-dose Radiotherapy in Patients With Stage IVb Esophageal Squamous Cell Carcinoma — OTHER · PHASE2
• Pembrolizumab in Post Radical Operation ESCC Patients With Lymph Node Positive ( KEYSTONE-004 ) — OTHER · PHASE2
• TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer — OTHER · NA

Refine this search